Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

5.950 +0.070 (+1.19%)
Streaming Delayed Price Updated: 10:23 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 489,032
Open 5.800
Bid (Size) 5.950 (100)
Ask (Size) 5.960 (3,000)
Prev. Close 5.880
Today's Range 5.700 - 6.000
52wk Range 1.540 - 9.750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
From Nuvation Bio
Via Business Wire

Performance

YTD
-30.7%
-30.7%
1 Month
-1.0%
-1.0%
3 Month
+24.0%
+24.0%
6 Month
+121.2%
+121.2%
1 Year
+156.5%
+156.5%

More News

Read More
News headline image
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
From Nuvation Bio and Eisai
Via Business Wire
Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut ↗
Via Stocktwits
News headline image
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
4 Analysts Assess Nuvation Bio: What You Need To Know ↗
Via Benzinga
News headline image
Analyst Expectations For Nuvation Bio's Future ↗
Via Benzinga
News headline image
Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance
Via MarketMinute
News headline image
Which stocks are moving on Wednesday? ↗
Via Chartmill
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Nuvation Bio (NUVB) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
News headline image
Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nuvation Bio to Participate in Upcoming Investor Conferences
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
From Nuvation Bio
Via Business Wire
News headline image
Why Nuvation Bio Stock Is Skyrocketing Today ↗
Via The Motley Fool
News headline image
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
News headline image
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio
Via Business Wire
News headline image
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
From Nuvation Bio
Via Business Wire

Frequently Asked Questions

Is Nuvation Bio Inc. Class A Common Stock publicly traded?
Yes, Nuvation Bio Inc. Class A Common Stock is publicly traded.
What exchange does Nuvation Bio Inc. Class A Common Stock trade on?
Nuvation Bio Inc. Class A Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Nuvation Bio Inc. Class A Common Stock?
The ticker symbol for Nuvation Bio Inc. Class A Common Stock is NUVB on the New York Stock Exchange
What is the current price of Nuvation Bio Inc. Class A Common Stock?
The current price of Nuvation Bio Inc. Class A Common Stock is 5.950
When was Nuvation Bio Inc. Class A Common Stock last traded?
The last trade of Nuvation Bio Inc. Class A Common Stock was at 02/18/26 10:23 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.